Opana

See also: Generic Opana ER

Opana is a brand name of oxymorphone, approved by the FDA in the following formulation(s):

OPANA (oxymorphone hydrochloride - injectable; injection)

• 
  Manufacturer: ENDO PHARMS
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 1MG/ML ^[RLD]

OPANA (oxymorphone hydrochloride - tablet; oral)

• 
  Manufacturer: ENDO PHARMS
  
  Approval date: June 22, 2006
  
  Strength(s): 10MG ^[RLD][AB], 5MG ^[AB]

Has a generic version of Opana been approved?

Yes. The following products are equivalent to Opana:

oxymorphone hydrochloride tablet; oral

• 
  Manufacturer: ROXANE
  
  Approval date: September 27, 2010
  
  Strength(s): 10MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: February 15, 2011
  
  Strength(s): 10MG ^[AB], 5MG ^[AB]

Note: No generic formulation of the following product is available.

• oxymorphone hydrochloride - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Opana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Opana.

See also...

• Opana Consumer Information (Drugs.com)
• Opana Consumer Information (Wolters Kluwer)
• Opana Consumer Information (Cerner Multum)
• Opana Advanced Consumer Information (Micromedex)
• Opana AHFS DI Monographs (ASHP)
• Oxymorphone Consumer Information (Wolters Kluwer)
• Oxymorphone Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Oxymorphone Suppositories Consumer Information (Wolters Kluwer)
• Oxymorphone Tablets Consumer Information (Wolters Kluwer)
• Oxymorphone Consumer Information (Cerner Multum)
• Oxymorphone Advanced Consumer Information (Micromedex)
• Oxymorphone Injection Advanced Consumer Information (Micromedex)
• Oxymorphone Hydrochloride AHFS DI Monographs (ASHP)

Daktozin

In the US, Daktozin is a member of the drug class topical antifungals and is used to treat Diaper Rash.

Ingredient matches for Daktozin

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Daktozin in the following countries:

• Belgium


• Colombia


• Luxembourg


• New Zealand


• Peru

Zinc Oxide

Zinc Oxide is reported as an ingredient of Daktozin in the following countries:

• Luxembourg


• New Zealand

International Drug Name Search

Aplenzin

Aplenzin is a brand name of bupropion, approved by the FDA in the following formulation(s):

APLENZIN (bupropion hydrobromide - tablet, extended release; oral)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: April 23, 2008
  
  Strength(s): 174MG, 348MG ^[RLD], 522MG
  

Has a generic version of Aplenzin been approved?

No. There is currently no therapeutically equivalent version of Aplenzin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aplenzin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Modified release formulations of a bupropion salt
  Patent 7,241,805
  Issued: July 10, 2007
  Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Turchetta; Stefano & Jackson; Graham & Massardo; Pietro & Saleh; Mohammad Ashty
  Assignee(s): Biovail Laboratories, Inc.
  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  



• 
  Modified release formulations of a bupropion salt
  Patent 7,569,610
  Issued: August 4, 2009
  Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty
  Assignee(s): Biovail Laboratories International SRL
  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
  
  



• 
  Modified release formulations of a bupropion salt
  Patent 7,572,935
  Issued: August 11, 2009
  Inventor(s): Oberegger; Werner & Maes; Paul & Turchetta; Stefano & Massardo; Pietro & Saleh; Mohammad Ashty
  Assignee(s): Biovail Laboratories International S.R.L.
  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  



• 
  Modified release formulations of a bupropion salt
  Patent 7,585,897
  Issued: September 8, 2009
  Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
  Assignee(s): Biovail Laboratories International S.r.l.
  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  



• 
  Bupropion hydrobromide and therapeutic applications
  Patent 7,645,802
  Issued: January 12, 2010
  Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty & Jackson; Graham
  Assignee(s): Biovail Laboratories International SRL.
  Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  



• 
  Modified release formulations of a bupropion salt
  Patent 7,649,019
  Issued: January 19, 2010
  Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
  Assignee(s): Biovail Laboratories International S.R.L.
  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  



• 
  Modified release formulations of a bupropion salt
  Patent 7,662,407
  Issued: February 16, 2010
  Inventor(s): Oberegger; Werner & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
  Assignee(s): Biovail Laboratories International S.R.L.
  The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  



• 
  Bupropion hydrobromide and therapeutic applications
  Patent 7,671,094
  Issued: March 2, 2010
  Inventor(s): Williams; Robert Parry & Silverstone; Peter Harris
  Assignee(s): Biovail Laboratories International S.R.L.
  Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
  
  Patent expiration dates:
  
  
  • June 27, 2026
    
    ✓ 
    Drug product
  
  

See also...

• Aplenzin Consumer Information (Drugs.com)
• Aplenzin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Aplenzin Consumer Information (Cerner Multum)
• Aplenzin Advanced Consumer Information (Micromedex)
• Bupropion Consumer Information (Drugs.com)
• Bupropion Consumer Information (Wolters Kluwer)
• Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Consumer Information (Cerner Multum)
• Bupropion Advanced Consumer Information (Micromedex)
• Bupropion Hydrochloride AHFS DI Monographs (ASHP)

Calcium Chloride

In some countries, this medicine may only be approved for veterinary use.

In the US, Calcium Chloride (calcium chloride systemic) is a member of the drug class minerals and electrolytes and is used to treat Asystole, Electromechanical Dissociation, Hyperkalemia, Hypermagnesemia and Hypocalcemia.

US matches:

• Calcium Chloride

ATC (Anatomical Therapeutic Chemical Classification)

A12AA07,B05XA07,G04BA03

CAS registry number (Chemical Abstracts Service)

0010043-52-4

Chemical Formula

Ca-Cl2

Molecular Weight

110

Therapeutic Categories

Electrolyte solution

Mineral supplement

Urological, acidifier

Treatment of parturient paresis (milk fever) in animals

Chemical Name

Calcium chloride

Foreign Names

• Calcii chloridum (Latin)
• Calciumchlorid (German)
• Chlorure de calcium (French)
• Calcio cloruro (Spanish)

Generic Names

• Calcium chloratum (IS)
• Calcium dichloride (IS)
• Chlorid vapenaty (IS)
• E 509 (IS)
• EINECS 233-140-8 (IS)
• Calcium Chloride (PH: USP 32)
• UNII-M4I0D6VV5M (IS)
• Calcii chloridum dihydricum (PH: Ph. Eur. 6)
• Calcium Chloride (PH: USP 31)
• Calcium Chloride Dihydrate (PH: BP 2010, Ph. Eur. 6)
• Calcium Chloride Hydrate (PH: JP XV)
• Calciumchlorid-Dihydrat (PH: Ph. Eur. 6)
• Calcium dichloride hexahydrate (IS)
• Calcii chloridum hexahydricum (PH: Ph. Eur. 6)
• Calcium chloride hexahydrate (PH: BP 2007, BP 2007, Ph. Eur. 6)
• Calcium Chloride Hexahydrate (PH: BP 2010)
• Calciumchlorid-Hexahydrat (PH: Ph. Eur. 6)

Brand Names

• Calcio + Magnesio Cloruro Fresenius (Calcium Chloride and Magnesium Chloride)
  Fresenius, Italy



• Calcio + Magnesio Cloruro Galenica (Calcium Chloride and Magnesium Chloride)
  Galenica Senese, Italy



• Calcio + Magnesio Cloruro Monico (Calcium Chloride and Magnesium Chloride)
  Monico, Italy



• Calcio + Magnesio Cloruro Salf (Calcium Chloride and Magnesium Chloride)
  Salf, Italy



• Calcium Chloratum
  Polfa Lódz, Poland



• Calcium Chloride
  CSL, Australia; Hospira, Canada; IMS, Oman; Phebra, Australia



• Calcium enriched Molasses (veterinary use)
  Agri-Feeds Limited, New Zealand



• Calcium Gel (veterinary use)
  Intervet, France



• Calciumchlorid Fresenius
  Fresenius Kabi, Austria



• Calcoral (veterinary use)
  Ausrichter, New Zealand



• Calol (Calcium Chloride and Magnesium (veterinary use))
  Prodivet - Coméercio de Produtos Químicos, Farmacêuticos e Cosméticos, Lda., Portugal; Provet, Switzerland



• Chlorure de Calcium
  Unimed, Tunisia



• Conclyte-Ca
  Nipro PharmaNipurofama, Japan



• Oral Cal (veterinary use)
  Bomac, New Zealand



• Toniflash (Calcium Chloride and Magnesium Chloride (veterinary use))
  Fort Dodge Santé Animale, France



• Accusol 35
  Baxter, Norway



• Accusol 35 Kalium
  Baxter, Norway



• Calcio Cloruro Bioindustria Lim
  Bioindustria Lim, Italy



• Calcio Cloruro Galenica
  Galenica Senese, Italy



• Calcio Cloruro Monico
  Monico, Italy



• Calcio Cloruro Salf
  Salf, Italy



• Calcium Chloratum
  Ivax, Slovakia



• Calcium Chloride
  AFT, New Zealand; Otsuka, Japan



• Calciumchlorid Baxter
  Baxter, Germany



• Calciumchlorid SAD
  SAD, Denmark



• Calmasel (Calcium Chloride and Magnesium Chloride hexahydrate (veterinary use))
  Selecta, Germany



• Intergravin (veterinary use)
  Alvetra u. Werfft, Austria



• Kovel (Calcium Chloride and Magnesium chloride (veterinary use))
  Gräub, Switzerland



• Sabax Calcium Chlorid
  Adcock Ingram Critical Care, South Africa



• Calcimag (Calcium Chloride and Magnesium Chlorid (veterinary use))
  Kela, Norway



• Calcium Chloratum Biotika
  Biotika, Slovakia



• Calcium Chlorure Cooper
  Cooper, France



• Calcium Richter forte (veterinary use)
  Richter, Austria



• Calcoral (veterinary use)
  Ausrichter, Australia



• CAL-MAG (Calcium Chloride and Magnesium (veterinary use))
  Streuli Vet, Switzerland



• Chlor-Mag-Kalz-Lösung (Calcium Chloride and Magnesium Chloride hexahydrate (veterinary use))
  WDT, Germany



• Chlorure de Calcium Renaudin
  Renaudin, France



• Cloruro Calcico Braun
  Braun, Spain



• Oral Cal (veterinary use)
  Bomac Animal Health, Australia



• Vélical (Calcium Chloride and Magnesium Chloride (veterinary use))
  Fort Dodge Santé Animale, France

International Drug Name Search

Glossary

IS	Inofficial Synonym
PH	Pharmacopoeia Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Acide méclofénamique

Acide méclofénamique may be available in the countries listed below.

Ingredient matches for Acide méclofénamique

Meclofenamic Acid

Acide méclofénamique (DCF) is also known as Meclofenamic Acid (Rec.INN)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Paracetamol-Darnitsa

Paracetamol-Darnitsa may be available in the countries listed below.

Ingredient matches for Paracetamol-Darnitsa

Paracetamol

Paracetamol is reported as an ingredient of Paracetamol-Darnitsa in the following countries:

• Georgia

International Drug Name Search

Profasi

In the US, Profasi (chorionic gonadotropin (hcg) systemic) is a member of the drug class gonadotropins and is used to treat Female Infertility, Hypogonadism - Male, Ovulation Induction and Prepubertal Cryptorchidism.

US matches:

• Profasi HP


• Profasi

Ingredient matches for Profasi

Chorionic Gonadotrophin

Chorionic Gonadotrophin is reported as an ingredient of Profasi in the following countries:

• Greece


• India


• Ireland


• Luxembourg


• Peru

International Drug Name Search